- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07942246
Healing and Improving Postnatal Nights Through Sleep (HIPNoS) (HIPNoS)
Healing and Improving Postnatal Nights Through Sleep (HIPNoS): A Randomized Controlled Trial Evaluating Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) in Postpartum Women With Insomnia and Depression.
Insomnia and depression are highly prevalent during postpartum, but effective treatment options are severely limited. Perinatal Understanding of Mindful Awareness (PUMAS) combines behavioral sleep strategies and mindfulness-based exercises to improve sleep and mood during pregnancy. Indeed, PUMAS has been shown to effectively treatment comorbid insomnia and depression in pregnancy in controlled and uncontrolled trials. The present randomized controlled trial (RCT) will evaluate the effectiveness of PUMAS in a sample of postpartum women with comorbid insomnia and depression who will be randomized to to telemedicine PUMAS or online sleep hygiene education (SHE; enhanced usual care). Patients will be treated for six weeks followed by assessment after treatment then follow-up assessment 3-months later. The investigators hypothesize that PUMAS patients, relative to SHE patients, will report superior acute treatment effects on insomnia and depression as well as more durable effects at 3-month follow-up.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Heba Research Operations Manager
- Número de teléfono: (248) 344-7363
- Correo electrónico: hafaneh1@HFHS.ORG
Ubicaciones de estudio
-
-
Michigan
-
Novi, Michigan, Estados Unidos, 48377
- Henry Ford Medical Center - Columbus
-
Contacto:
- Heba Research Operations Manager
- Número de teléfono: (248) 344-7363
- Correo electrónico: hafaneh1@HFHS.ORG
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial
- Participant must be able to engage in treatment (e.g., has internet access to attend telemedicine appointments or access online sleep hygiene materials).
- Aged 18 years or above.
- Postpartum 4-12 months at time of screening.
- Meets diagnostic criteria for DSM-5 insomnia disorder, acute (symptoms lasting ≥1 month).
- Clinically severe insomnia symptom severity (Insomnia Severity Index score ≥11).
- Clinically significant depression symptoms (Edinburg Postnatal Depression Scale score ≥10).
Exclusion Criteria:
- Sleep complaints primarily due to infant sleep problems as ascertained via clinical interview and/or describing the infant's sleep as a 'moderate' or 'serious' problem on the Brief Infant Sleep Questionnaire on the screening survey.
- Suicidal intent per the Columbus Suicide Severity Rating Scale (Suicidal ideation WITHOUT intent is NOT exclusionary).
- Current engagement in psychotherapy for insomnia disorder (current use of sleep aids [prescription, over-the-counter, or dietary supplements] is NOT exclusionary).
- Night or rotating shift work.
- Unreliable internet access that prevents a patient from being to engage with treatment and/or assessments.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
Participants assigned to receive the PUMAS intervention. |
A six-week psychotherapy protocol combining behavioral sleep strategies with mindfulness exercises with all components tailored to peripartum. PUMAS was initially developed for pregnancy and has been shown to be safe and effective for alleviating insomnia, depression, and cognitive arousal during pregnancy. Early evidence from real-world clinic data has shown that postpartum women with insomnia show the same treatment benefits as prenatal patients, thereby offering early support for effectiveness in pregnancy. PUMAS will be delivered via telemedicine video with a therapist. |
|
Otro: Sleep hygiene education (SHE)
Participants assigned to receive six weeks of educational materials as an enhanced usual-care control. |
Sleep hygiene education (SHE) on maternal sleep and infant sleep. A six-week psychoeducation that will be delivered via six weekly information sheets that will be delivered via email to patients. Perinatal patients report that SHE is the most recommended non-pharmacological treatment suggested for their insomnia. In the real world, SHE is typically delivered in a one-shot information sheet (e.g., after visit summary). However, to match for contact frequency, SHE information will be delivered to patients weekly across six weeks, which also allows for providing greater information on maternal and infant sleep, thereby representing enhanced usual care practice. Although SHE practices improve sleep quality, SHE is not considered an effective standalone treatment for insomnia, therefore making SHE an interventional control comparator. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Insomnia Severity Index (ISI)
Periodo de tiempo: The investigators will examine change in ISI from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Insomnia Severity Index is a commonly used self-report measure of insomnia symptoms that has been validated in peripartum. ISI scores range from 0 to 28 with higher scores indicating greater insomnia severity. |
The investigators will examine change in ISI from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Edinburgh Postnatal Depression Scale (EPDS)
Periodo de tiempo: The investigators will examine change in EPDS from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Edinburgh Postnatal Depression Scale (EDPS) is the most widely use depression measure in pregnancy and postpartum. EPDS scores range from 0 to 30 with higher scores indicating greater depression severity. |
The investigators will examine change in EPDS from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
|
Pre-Sleep Arousal Scale's cognitive factor (PSASC)
Periodo de tiempo: The investigators will examine change in PSASC from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in peripartum. PSASC scores range 8 to 40 with higher scores indicating greater nocturnal cognitive arousal. |
The investigators will examine change in PSASC from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: David A. Kalmbach, PhD, Henry Ford Health
Publicaciones y enlaces útiles
Publicaciones Generales
- Kalmbach DA, Cheng P, Roth T, Swanson LM, Cuamatzi-Castelan A, Roth A, Drake CL. Examining Patient Feedback and the Role of Cognitive Arousal in Treatment Non-response to Digital Cognitive-behavioral Therapy for Insomnia during Pregnancy. Behav Sleep Med. 2022 Mar-Apr;20(2):143-163. doi: 10.1080/15402002.2021.1895793. Epub 2021 Mar 15.
- Swanson LM, Flynn H, Adams-Mundy JD, Armitage R, Arnedt JT. An open pilot of cognitive-behavioral therapy for insomnia in women with postpartum depression. Behav Sleep Med. 2013;11(4):297-307. doi: 10.1080/15402002.2012.683902. Epub 2012 Dec 6.
- Kalmbach DA, Cheng P, Drake CL. A pathogenic cycle between insomnia and cognitive arousal fuels perinatal depression: exploring the roles of nocturnal cognitive arousal and perinatal-focused rumination. Sleep. 2021 Jun 11;44(6):zsab028. doi: 10.1093/sleep/zsab028.
- Kalmbach DA, Cheng P, Ong JC, Ciesla JA, Kingsberg SA, Sangha R, Swanson LM, O'Brien LM, Roth T, Drake CL. Depression and suicidal ideation in pregnancy: exploring relationships with insomnia, short sleep, and nocturnal rumination. Sleep Med. 2020 Jan;65:62-73. doi: 10.1016/j.sleep.2019.07.010. Epub 2019 Jul 22.
- Kalmbach DA, Cheng P, Sangha R, O'Brien LM, Swanson LM, Palagini L, Bazan LF, Roth T, Drake CL. Insomnia, Short Sleep, And Snoring In Mid-To-Late Pregnancy: Disparities Related To Poverty, Race, And Obesity. Nat Sci Sleep. 2019 Nov 4;11:301-315. doi: 10.2147/NSS.S226291. eCollection 2019.
- Kalmbach DA, Ong JC, Cheng P, Reffi AN, Swanson LM, Hirata M, Seymour GM, Castelan-Cuamatzi AS, Jennings MB, Pitts DS, Roth A, Roth T, Drake CL. A randomized controlled trial of telemedicine CBTI and PUMAS for prenatal insomnia: Reducing nocturnal cognitive arousal is a treatment mechanism for alleviating insomnia and depression during pregnancy. Sleep Med. 2025 Sep;133:106570. doi: 10.1016/j.sleep.2025.106570. Epub 2025 May 12.
- Kalmbach DA, Cheng P, Reffi AN, Ong JC, Swanson LM, Fresco DM, Walch O, Seymour GM, Fellman-Couture C, Bayoneto AD, Roth T, Drake CL. Perinatal Understanding of Mindful Awareness for Sleep (PUMAS): A single-arm proof-of-concept clinical trial of a mindfulness-based intervention for DSM-5 insomnia disorder during pregnancy. Sleep Med. 2023 Aug;108:79-89. doi: 10.1016/j.sleep.2023.05.026. Epub 2023 Jun 10.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Síntomas de comportamiento
- Trastornos del sueño y la vigilia
- Trastornos del Sueño Intrínsecos
- Disomnias
- Comportamiento
- Depresión
- Trastornos de iniciación y mantenimiento del sueño
- Fenómenos fisiológicos musculoesqueléticos y neuronales
- Sistema nervioso Fenómenos fisiológicos
- Dormir
Otros números de identificación del estudio
- 19940
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .